US 12,303,505 B2
Tumor-treating pharmaceutical composition
Yoichi Ozawa, Tsukuba (JP); Yusaku Hori, Tokyo (JP); Kazuhiko Yamada, Tsukuba (JP); Hiroshi Kamiyama, Tsukuba (JP); and Masahiro Matsuki, Tsukuba (JP)
Assigned to Eisai R&D Management Co., Ltd., Tokyo (JP)
Appl. No. 16/465,277
Filed by Eisai R&D Management Co., Ltd., Tokyo (JP)
PCT Filed Feb. 6, 2018, PCT No. PCT/JP2018/004007
§ 371(c)(1), (2) Date May 30, 2019,
PCT Pub. No. WO2018/147275, PCT Pub. Date Aug. 16, 2018.
Claims priority of application No. 2017-021542 (JP), filed on Feb. 8, 2017.
Prior Publication US 2019/0388420 A1, Dec. 26, 2019
Int. Cl. A61K 31/4985 (2006.01); A61K 31/53 (2006.01); A61P 35/00 (2006.01)
CPC A61K 31/4985 (2013.01) [A61K 31/53 (2013.01); A61P 35/00 (2018.01)] 21 Claims
 
1. A method for treating a tumor, comprising administering a therapeutically effective amount of lenvatinib or a pharmaceutically acceptable salt thereof, and (6S,9aS)—N-benzyl-8-({6-[3-(4-ethylpiperazin-1-yl)azetidin-1-yl]pyridin-2-yl}methyl)-6-(2-fluoro-4-hydroxybenzyl)-4,7-dioxo-2-(prop-2-en-1-yl)hexahydro-2H-pyrazino[2,1-c][1,2,4]triazine-1(6H)-carboxamide to a patient in need thereof, wherein the tumor is breast cancer, a thyroid cancer, hepatocellular carcinoma, colorectal cancer, renal cell carcinoma, head and neck cancer, endometrial cancer, or melanoma.